Michael Egholm - 08 Apr 2024 Form 4 Insider Report for STANDARD BIOTOOLS INC. (LAB)

Role: President & CEO, Director
Signature: /s/ Michael Egholm by Agnieszka Gallagher, Attorney-in-Fact
Issuer symbol: LAB
Transactions as of: 08 Apr 2024
Net transactions value: -$277,948
Form type: 4
Filing time: 09 Apr 2024, 19:11:29 UTC
Previous filing: 05 Apr 2024
Next filing: 21 May 2024
SEC: View on sec.gov

Quoteable Key Fact

"Michael Egholm filed Form 4 for STANDARD BIOTOOLS INC. (LAB) on 09 Apr 2024."

Quick Takeaways

This page summarizes Michael Egholm's Form 4 filing for STANDARD BIOTOOLS INC. (LAB).
1 reported transaction and 0 derivative rows are listed below.
Filing timestamp: 09 Apr 2024, 19:11.

What Changed

Previous filing in this sequence was filed on 05 Apr 2024.
Current net transaction value: -$277,948.

Why This Matters

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Source Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

See Original Filing

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	LAB	Common Stock	Tax liability	$277,948	-102,564	-16%	$2.71	531,592	08 Apr 2024	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain performance-based restricted stock units ("RSUs") granted to the reporting person on April 11, 2023, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on April 5, 2024 upon the determination by the Board of Directors of the Issuer that certain of the performance-based conditions were met.

Content

The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain performance-based restricted stock units ("RSUs") granted to the reporting person on April 11, 2023, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on April 5, 2024 upon the determination by the Board of Directors of the Issuer that certain of the performance-based conditions were met.